← All trials
NCT05826054
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2023
- Primary completion
- May 31, 2024
- Completion date
- May 31, 2024
- First posted
- Apr 24, 2023
- Last posted
- Dec 13, 2023
- Enrollment
- 25
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of British ColumbiaLead sponsor
- Michael Smith Foundation for Health ResearchCollaborator
- University of British ColumbiaOverall official - principal investigator
- University of British ColumbiaSponsor investigator
- University of British ColumbiaOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.